IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#21

In re patent application of:

Bernhart et al.

5,270,317

IROP med: December 14, 1993

Serial No. 08/794,497

Filing Date: November 20, 1991

For: N-Substituted Heterocyclic Derivatives, Their Preparation And The Pharmaceutical Compositions In Which They Are Present

Assistant Commissioner for Patents Box Patent Extension Washington, D.C. 20231 **CERTIFICATE UNDER 37 C.F.R. 1.10(b)**

Express Mail Label Number: EM317281351US

Date of Deposit: 18 November 1997

I hereby certify that this paper is being deposited with the United Stated Postal Service "Express Mail Post Office to Addressee" Service on the indicated above and is addressed to: Asst. Commissioner for Patents

Box Patent Extension, Washington, DC 20231

Name

18 November 1997

Date

RECEIVED

DEC - 1 1997

PATENT EXTENSION

AC PATENTS

Dear Sir:

TRANSMITTAL LETTER APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 USC 156 and 37 CFR 1.740

Under the provisions of 35 USC 156 and 37 CFR 1.740 applicants hereby request an extension of the patent term of U.S. Patent No. 5,270,317, issued December 14, 1993.

Enclosed are:

- 1. An Application for Extension of Patent Term under 35 U.S.C. 156 and 37 CFR 1.740 which includes the following attachments:
 - a) a copy of FDA approval letter for NDA 20-757;
 - b) a copy of U.S. Patent No. 5,270,317;
 - c) a copy of the receipt of Maintenance Fee Statement for U.S. Patent No. 5,270,317;
 - d) a copy of a Certificate of Correction for U.S. Patent No. 5,270,317; and
 - e) a copy of a Terminal Disclaimer for U.S. Patent No. 5,270,317.
- 2. Declaration under 37 CFR 1.740(b) of Michael D. Alexander, Agent for Applicants
- 3. Certification
- 4. Fee of \$1120.00 to be charged to Deposit Account No. 19-0091. (A duplicate copy of this notice is enclosed.)

The Commissioner is hereby authorized to charge any other fees associated with the extension of this patent to our Deposit Account No. 19-0091.

Respectfully submitted,

Date: No UCmber 18 1997

Metal O. alexand Michael D. Alexander, Agent For Applicant(s)

Registration No. 36,080

Address:

Sanofi Pharmaceuticals, Inc. Patent Department 9 Great Valley Parkway Malvern, PA 19355 Tele: (610) 889-8802

Facsimile: (610) 889-8799

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Application of: n re paten

Patent No.: 5,270,317

Granted: December 14, 1993

Serial No. 08/794,497

Filing Date: November 20, 1991

For: N-Substituted Heterocyclic Derivatives, Their Preparation And The Pharmaceutical Compositions In Which They Are Present

Assistant Commissioner for Patents Box Patent Extension Washington, D.C. 20231

CERTIFICATE UNDER 37 C.F.R. 1.10(b)

Express Mail Label Number: EM317281351US

18 November Date of Deposit: I hereby certify that this paper is being deposited with the United Stated Postal Service "Express Mail Post Office to Addressee" Service on the indicated above and is addressed to: Asst. Commissioner for Patents Box Patent Extension, Washington, DC 20231

Name

Date

RECEIVED

APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 USC 156 AND 37 CFR 1,740

Dear Sir:

Under the provisions of 35 U.S.C. 156 and in accordance with 37 CRF 1.740, Sanofi, the owner of record of United States Patent 5,270,317 which claims the human drug product irbesartan, respectfully, requests that the term of said patent, originally expiring March 20, 2011, be extended by 194 days to expire on September 30, 2011. Sanofi and Bristol-Myers Squibb Company cooperated in the obtaining regulatory approval of this human drug product.

(1) Irbesartan is the generic name for the compound having the chemical name 2-butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4,4]non-1-en-4-one, and having the structural formula:

- (2) Irbesartan was subject to regulatory review by the Food and Drug Administration (FDA) under Sections 505(i) and 505(b) of the Federal Food, Drug and Cosmetic Act.
- (3) Irbesartan having the tradename AVAPRO® was approved for commercial marketing or use by the Food and Drug Administration under Section 505(b) of the Federal Food, Drug and Cosmetic Act on September 30, 1997 as evidenced by a copy of the letter of approval attached hereto dated September 30, 1997.
- (4) The active ingredient in the approved product is irbesartan. Irbesartan has not been previously approved for commercial marketing or use under the Federal Food, Drug and Cosmetic Act.
- (5) This application is being submitted within the sixty day period pursuant to 37 CFR §1.720(f). The last day on which this application can be submitted is November 29, 1997.
- (6) The patent for which an extension is being sought is Claude Bernhart, Jean-Claude Breliere, Jacques Clement, Dino Nisato, Pierre Perrault, Claude Muneaux and Yvette Muneaux, United States Patent 5,270,317, issued December 14, 1993, having a normal expiration of March 20, 2011.
- (7) A complete copy of United States Patent 5,270,317, including the entire specification and claims, is attached hereto.
- (8) A receipt of maintenance fee payment dated June 13, 1997, for United States Patent 5,270,317 is also attached hereto. A copy of a Certificate of Correction dated July 22, 1997, and a copy of a Terminal Disclaimer dated May 24, 1994 are also attached.
- (9) United States Patent 5,270,317 claims irbesartan as a composition of matter (compound) and in pharmaceutical compositions. The applicable claims are as follows:

Claim 1 (compound). Claim 1 reads on irbesartan. Specifically, irbesartan is a compound having the specified structural formula wherein R_1 is a tetrazolyl, R_2 is hydrogen, R_3 is a C_1 - C_6 alkyl which is unsubstituted, t and z are 0, R_4 and R_5 together are a group of the formula $(CH_2)_n$, X is an oxygen atom and n is an integer from 2-11.

Claim 2 (compound). Claim 2 reads on compounds of claim 1 wherein R_1 is in the ortho position and is a tetrazolyl group and R_2 is hydrogen.

Claim 3 (compound). Claim 3 reads on compounds of claim 1 wherein R_4 and R_5 form a cyclopentane with the carbon to which they are bonded.

Claim 5 (compound). Claim 5 reads on compounds of claim 1 wherein R_3 is a linear C_1 - C_6 alkyl group.

Claim 6 (compound). Claim 6 reads on compounds of claim 1 wherein X is oxygen.

Claim 7 (compound). Claim 7 reads on compounds of claim 1 wherein z = t = 0.

Claim 8 (compound). Claim 8 reads on a compound which is 2-n-butyl-4-spirocyclopentane-1-[(2'(tetrazol-5-yl)biphenyl-4-yl)methyl]-2-imidazolin-5-one.

Claim 10 (composition). Claim 10 reads on a pharmaceutical composition containing the approved product as defined in claim 1 above.

(10) Irbesartan was subject to a regulatory review period consisting of (a) the period from April 30, 1993, the effective date of Investigational New Drug Application No. 41,926 (the "IND") under Section 505(i) of the Federal Food, Drug and Cosmetic Act (30 days after the IND was received by the FDA), to September 26, 1996, the initial submission date of New Drug Application No. 20-757 (the "NDA") under Section 505(b) of the Federal Food, Drug and Cosmetic Act; and (b) the period from September 26, 1996, the NDA submission date, to September 30, 1997, the date of approval of the NDA.

(11) The significant activities undertaken by or on behalf of Sanofi and responses by the FDA during the applicable review period with respect to the approved product are as follows:

DATE	ACTIVITY
March 30, 1993	Submission of IND application for irbesartan
March 31, 1993	FDA acknowledgment of receipt of IND; assignment of IND number 41,926
April 29, 1993	Effective date of IND
July 1, 1993	FDA request for information regarding CMC section of IND with
	recommendations.
August 26, 1993	Letter received from FDA sharing views regarding labeling.
August 31, 1993	Submission of new protocol, new investigator information, and CMC
September 16, 1993	Submission of information amendment regarding pharmacology/toxicology request for FDA comment.
January 7, 1994	Submission of information amendment regarding pharmacology/ toxicology with request for FDA comment. Also submit draft protocol.
February 3, 1994	Response to FDA request for information
February 7, 1994	Response to FDA request for information
April 27, 1994	Response to FDA request for information
May 12, 1994	Submission of information regarding non-IND study
May 25, 1994	Submission of pharmacology/toxicology final parts and amendments for preclinical.
August 19, 1994	Submission of 8 preclinical reports
September 8, 1994	End-of-Phase II Meeting submission
September 26, 1994	Submitted revisions to End-of-Phase II meeting submission
September 29, 1994	End-of-Phase II Meeting between FDA
October 18, 1994	Submission of End-of-Phase II Meeting draft minutes
October 26, 1994	Submission of pharmacology/ toxicology reports
October 31, 1994	Attachments submitted to IND regarding CMC, clinical supplies and additional packaging and labeling site. Also submitted new protocol, new investigator and CMC
November 14, 1994	FDA request for information; submission of preliminary toxicokinetic data
January 20, 1995	Submission of information amendment regarding clinicals

DATE	ACTIVITY			
January 25, 1995	Submission of protocol amendment with new protocol and			
1007	information amendment regarding CMC			
March 13, 1995	Submission of protocol amendment regarding new protocol and			
	information amendment regarding CMC			
June 26, 1995	Request for meeting with FDA			
July 20, 1995	Request submitted for review and comment of study			
July 26, 1995	Meeting with FDA			
August 21, 1995	Meeting minutes from July 26, 1995 meeting			
October 13, 1995	Submission of information amendment regarding pharmacology/			
	toxicology - Request for FDA comments.			
October 19, 1995	Minutes of meeting with FDA regarding proposed study in patients			
	with Type II Diabetes and nephropathy.			
October 24, 1995	Conversation with FDA and D. Hay regarding ongoing study			
November 3, 1995	Submission of CMC information and request for pre-NDA CMC meeting			
December 20, 1995	Pre-NDA CMC meeting with FDA			
January 18, 1996	Request for DA review and comment (re. NDA filings)			
February 8, 1996	Pre-NDA meeting			
February 14, 1996	Received FDA summary of December 20, 1995 CMC meeting			
February 16, 1996	Request for FDA review and comment			
February 28, 1996	Submitted meeting minutes			
March 13, 1996	Response to FDA			
July 19, 1996	Submission of eight preclinical report			
August 8, 1996	Submission of six pharmacology/toxicology reports			
September 4, 1996	Letter summarizing agreements reached with FDA regarding format and content of NDA submission			
September 26, 1996	NDA submitted			
December 6, 1996	Meeting with FDA			
December 11, 1996	Received FDA comments on submission of November 1, 1996			
January 24, 1997	Submitted minutes of meeting of December 6, 1996			
February 11, 1997	Received FDA's summary of End of Phase II Meeting held on December 6, 1996			

DATE	ACTIVITY
July 21, 1997	Request for FDA comment
August 14, 1997	Received FDA comments
September 26, 1997	Date of FDA approvable letter
September 30, 1997	Date of FDA approval letter for NDA 20-757

- (12) In the opinion of the Applicant, this patent is eligible for an extension of 878 days before any reductions are applied. The length of said extension is calculated as follows: Irbesartan was subject to a total review period of 1615 days consisting of:
 - (a) The IND period from April 30, 1993 (the effective date of the IND) to September 26, 1996 (the initial submission of date of NDA 20-757) amounting to 1245 days (only 1017 days of which occurred after the issue date of U.S. Patent 5,270,317), and
 - (b) the NDA period from September 26, 1996 (the initial submission date of NDA 20-757) to September 30, 1997 (the NDA approval date) amounting to 370 days.

The patent term extension is then calculated as follows:

$$\underline{IND}$$
 + NDA = $\underline{1017}$ days + $\underline{370}$ days = $\underline{878}$ days
2 or approximately 2.4 years

This period is reduced to 194 days pursuant to 35 USC 156(c)(3) and 37 CFR 1.775(d)(4). According to these sections the patent term may be extended to the earlier of the date calculated by adding 14 years to the date of approval of the application, which was September 30, 1997, and the term calculated as set forth above. In this case, adding 14 years to the date of approval, which was September 30, 1997, would extend the term to September 30, 2011, an additional 194 days which is less than the approximately 2.4 years calculated above. Accordingly, it is respectfully submitted that U.S. patent No. 5,270,317 is eligible for an extension of 194 days until September 30, 2011.

A Terminal Disclaimer was submitted in July 1994 with respect to U.S. Patent No. 5,270,317 (the '317 patent) disclaiming the portion of the term of the '317 patent which would extend beyond the expiry of the full statutory term of U.S. Patent No. 5,268,375 (the '375 patent) which issued on December 7, 1993 one week before the issuance of the '317 patent. The '375 patent resulted from an application filed in the United States on February 28, 1992 before the enactment of the Uruguay Round Agreement Act. Pursuant to 35 U.S.C.§154(a)(2) the '375 patent is entitled to a term that is the greater of 20 years from the date the application from which it resulted was filed in the U.S. or 17 years from grant. In this case, 20 years from the filing date of the application in the U.S. is the greater term (February 28, 2012) resulting in the '375 patent having a longer statutory term than the '317 patent. The '317 patent resulted from an application containing specific reference to an earlier filed application filed in the U.S. on March 20, 1991. The term of the '371 patent, therefore, has a natural expiry date of March 20, 2011 as noted above.

(13) Sanofi acknowledges its duty to disclose to the Assistant Commissioner for Patents and the Secretary of Health and Human Services any information of which it is aware which is material to the determination of entitlement to the extension sought.

- (14) The Commissioner is hereby authorized to charge any fees in connection with this request to Deposit Account No. 19-0091.
- (15) Correspondence relating to this application should be directed to:

Michael D. Alexander Sanofi Pharmaceuticals, Inc. 9 Great Valley Parkway Malvern, PA 19355 Tele: (610) 889-8802

Telephone or facsimile communications relating to this application can be directed to the undersigned at the numbers listed below.

- (16) A certified duplicate of this application is submitted herewith.
- (17) A Declaration under 37 CFR §1.740(b) is also submitted herewith.

Respectfully submitted,

Dated: November 18, 1997

Michael D. Alexander Agent for Applicant Registration No. 36,080

Address:

Sanofi Pharmaceuticals, Inc. 9 Great Valley Parkway Malvern, PA 19355

Telephone: (610) 889-8802 Facsimile: (610) 889-8799



DEPARTMENT OF HEADH & HUMAN SERVICES




Food and Drug Administration Rockville MD 20857

SEP 3 0 1997

Sahofi Pharmaceuticals, Inc. Attention: Gregory Torre, Ph.D., J.D. 90 Park Avenue New York, NY 10016

Dear Dr. Torre:



Please refer to your September 26, 1996 new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Avapro (irbesartan) 75, 150 and 300 mg Tablets.

We acknowledge receipt of your amendments and correspondence dated August 21 and September 16 and 29, 1997.

This new drug application provides for the use of Avapro (irbesartan) Tablets in the treatment of hypertension.

We have completed the review of this application, including the submitted draft labeling, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed marked-up draft labeling. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed marked-up draft labeling. Marketing the product with FPL that is not identical to this draft labeling may render the product misbranded and an unapproved new drug.

Please submit sixteen copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy weight paper or similar material. For administrative purposes this submission should be designated "FINAL PRINTED LABELING" for approved NDA 20-757. Approval of this submission by FDA is not required before the labeling is used.

Should additional information relating to the safety and effectiveness of the drug become available, revision of that labeling may be required.

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

Please submit one market package of the drug when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

Jav dest'd #3834 If you have any questions, please contact:

Ms. Kathleen Bongiovanni Regulatory Health Project Manager (301) 594-5334

Sincerely yours,

Robert Temple, M.D.

Director

Office of Drug Evaluation I

Center for Drug Evaluation and Research

Enclosure

cc: Bris

Bristol-Myers Squibb Company

Attention: Douglas B. Hay, Ph.D.

P.O. Box 4000

Princeton, NJ 08543-4000



Patent and Tradez k Office COMMISSI Washington, Address: A OF PATENTS AND TRADEMARKS C. 20231

PAYOR NUMBER 000337

P75M ACCUMAS COMPUTER PACKAGES ANNUITY, 414 HUNGERFORD DRIVE SUITE 300 ROCKVILLE MD 20850

NOV 1 3 1997

RECEIVED

MAINTENANCE FEE STATEMENT

The data shown below is from the records of the Patent and Trademark Office. If the maintenance fees and any necessary surcharges have been timely paid for the patents listed below, the notation "PAID" will appear in column 10, "status" below.

if a maintenance fee payment is defective, the reason is indicated by code in column 10, "status" below. An explanation of the codes appears on the reverse of the Maintenance Fee Statement. TIMELY COR-RECTION IS REQUIRED IN ORDER TO AVOID EXPIRATION OF THE PATENT. NOTE 37 CFR 1.377. THE PAYMENT(S) WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION. IF PAYMENT OR CORRECTION IS SUBMITTED DURING THE GRACE PERIOD, A SURCHARGE IS ALSO REQUIRED. NOTE 37 CFR 1.20(k) and (i).

If the statement of small entity status is defective the reason is indicated below in column 10 for the related patent number. THE STATEMENT OF SMALL ENTITY STATUS WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION.

NBR	NUMBER		FEE AMOUNT	SUR CHARGE	serial Number	PATENT DATE	FILE DATE	PAY SML YR ENT	
1	5,270,317	183	1020		07/794,497	12/14/93	11/20/91		,

If the "status" column for a patent number listed above does not indicate "PAID" a code or an asterisk (*) will appear in the "status" column. Where an asterisk (*) appears, the codes are set out below by the related item number. An explanation of the codes indicated in the "status" column and as set out below by the related item number appears on the reverse of the maintenance fee statement.

> ITM NBR

ATTY DKT NUMBER

REF/CBDL505

DIRECT THE RESPONSE TOGETHER WITH ANY QUESTIONS ABOUT THIS NOTICE TO: COMMISSIONER OF PATENTS AND TRADEMARKS, BOX M, FEE, WASHINGTON, DC 20231

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. :

5,270,317

DATED

Fax émis par : 33 67106889

December 14, 1993

SR MTP BREVETS

INVENTOR(S):

Claude BERNHART et al.

It is certified that error appears in the above-indentified patent and that said Letters Patent is hereby corrected as shown below:

Column 1, line 59, delete "N-cyanoacetamide" and insert -- N-cyanocarbamovi-;

line 60, delete "hydroxyacetamide" and insert --hydroxycarbamoyi--;

line 61, delete "yl)acetamide" and insert --yl)carbamoyi--.

Column 9, line 37, delete "yl)acetamide" and insert -yl)carbamoyl-;

line 40, delete "N-hydroxyacetamide, N-cyanoacetamide" and insert --N-hydroxycarbamoyl, N-cyanocarbamoyl--.

"cyanocarboxamidebiphenyl" Column line 8, delete --cyanocarbamoylbiphenyi--.

line 52, delete "C--Cyanocarbamoylbiphenyl--. "Cyanocarboxamidebiphenyl" Column

Column 35, line 18, delete "ylacetamide" and insert therefor -ylcarbamoyi-.

Column 52, line 62, delete "N-cyanoacetamide" and insert -N-cyanocarbamoyi--;

line 63, delete "hydrooxyacetamide" and insert --hydrooxycarbamoyl-;

line 64, delet "yl)acetamide" and insert --yl)carbamoyi--.

Signed and Sealed this

Twenty-second Day of July, 1997

Suce Chorum

BRUCE LEHMAN

Attesting Officer

Commissioner of Patents and Trademarks

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1201

Examiner: Richter

In re U.S. Patent 5,270,317

Claude BERNHART et al.

Serial No. 07/794,497

Fax émis par : 33 67106889

Filed: November 20, 1991

EA.

N-Substituted heterocyclic derivatives, : their preparation and the pharmaceutical :

compositions in which they are present

TERMINAL DISCLAIMER

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

Your Petitioner, ELF SANOFI (henceforth referred to as "Assignee"), having a place of business at 32-34 rue Marbauf, Paris, France, represents that it is the owner by assignment of the entire right and title to the above-captioned patent and the invention and improvements therein disclosed for the United States by virtue of an Assignment from the inventors, Claud Bernhart et al., to SANOFI, dated February 3, 1992, and recorded at Reel 6011, Frame 0616, on February 11, 1992. SANOFI changed its name to ELF SANOFI on January 31, 1992, as reflected in the change of name document which was recorded in connection with the above patent on June 22, 1993, at Reel 6583, Frame 0399.

Assignes, who is also owner of the entire right and title to U.S. Patent Number 5,268,375 by an Assignment recorded on April 15, 1992, at Reel 6092, Frame 0530, hereby disclaims the terminal part of the above-captioned patent which would extend beyond the expiration date of the full statutory term of U.S. Patent Number 5,268,375, and hereby agrees that the above-captioned patent shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent Number 5,268,375, this agreement to run with the above-captioned patent to be binding upon the grantee, its successors or assigns. Notwithstanding the above disclaimer, Assignee does not waive any rights available under the provisions of 35 U.S.C. §§155 and 156.

07/11/97 15:50 Pg: 11/11

U.S. Patent No. 5.270.317

Assignee does not disclaim any terminal part of the above captioned patent prior to the expiration date of the full statutory term of U.S. Patent 5,268,375 in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term, except for the separation of legal title stated above. Assignee does not disclaim any terminal part of the above captioned patent resulting from any extension of that patent granted under the provisions of 35 U.S.C. §§155, 155(a) and 156.

Assignee certifies under 37 C.F.R. §3.73(b) that the evidentiary documents have been reviewed and, to the best of assignee's knowledge, title is in the assignee as reflected in the assignments and change of name documents referenced above.

Signed at Paris, France this day of May 1994.

Respectfully submitted,

ELF SANOFI

Name:

Title:

Ronald SCHAPIRA Chaf de la Division Proprié

Director of Patents and Trademarks





RIngre patent application of:

Bernhart et al.

Patent No.: 5,270,317

Granted: December 14, 1993

Serial No. 08/794,497

Filing Date: November 20, 1991

For: N-Substituted Heterocyclic Derivatives, Their Preparation And The Pharmaceutical Compositions In Which They Are Present **CERTIFICATE UNDER 37 C.F.R. 1.10(b)**

Express Mail Label Number: <u>EM317281351US</u>

Date of Deposit: 18 Novel 1997
I hereby certify that this paper is being deposited with the United Stated Postal Service "Express Mail Post Office to Addressee" Service on the indicated above and is addressed to: Asst. Commissioner for Patents Box Patent Extension, Washington, DC 20231

Name L. Qunt

Date

Assistant Commissioner for Patents Box Patent Extension Washington, D.C. 20231

Dear Sir:

DECLARATION UNDER 37 CFR §1.740(b)

I, MICHAEL D. ALEXANDER, do declare that:

- (1) I am an agent authorized to practice before the United States Patent and Trademark Office (Registration No. 36,080) having authority (as evidenced by the attached Power of Attorney) to act on behalf of Sanofi, a French Corporation duly organized under the laws of the Republic of France, having a place of business at 32-34, Rue Marbeuf, 75008 Paris, France, the sole owner of the entire right, title and interest in and to United States Patent 5,270,317 pursuant to the assignment recorded in the United States Patent and Trademark Office on February 11, 1992 at Reel 6011, Frames 615 and 616; the change of name from Sanofi to Elf Sanofi recorded in the United States Patent and Trademark Office on June 22, 1993 at Reel 6583, Frames 399-403; and the change of name from Elf Sanofi to Sanofi recorded in the United States Patent and Trademark Office on July 22, 1997 at Reel 8613, Frame 0145-0149.
- (2) I have reviewed and understand the contents of the application submitted herewith in duplicate for extension of the term of United States Patent 5,270,317 under the provisions of 37 §1.740;

DN 80111

- (3) I believe the patent is subject to extension pursuant to 37 CFR §1.710;
- (4) I believe an extension of the length claimed is justified under 35 USC §156 and the applicable regulations; and
- (5) I believe the patent for which the extension is being sought meets the conditions for extension of the term of a patent as set forth in 37 CFR §1.720.

I further declare that all statements made herein of my own knowledge are true and all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Respectfully submitted,

Dated: November 18, 1997

Michael D. Alexander Agent for Applicant Registration No. 36,080

Without O. desarle

Address:

Sanofi Pharmaceuticals, Inc. 9 Great Valley Parkway Malvern, PA 19355
Tele: (610) 889-8802

Facsimile: (610) 889-8799

Docket No. 80111 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Patent of: Claude Bernhart et al.

5,270,317

I hereby certify that this correspondence is being deposited on the date indicated below

with the United States Postal Service as first

class mail addressed to:

Assistant Commissioner for Patents,

Washington, D.C. 20231

Muhala. Des

Name

07/794,497

Filing Date:

November 20, 1991

December 14, 1993

Date

FOR:

1997 Extent No.:

Grant Date:

Serial No.:

N-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS IN WHICH THEY ARE PRESENT

POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST (REVOCATION OF PRIOR POWERS)

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

As assignee of record of the entire interest of the above-identified patent,

REVOCATION OF PRIOR POWERS OF ATTORNEY

all powers of attorney previously given are hereby revoked and

NEW POWER OF ATTORNEY

the following attorneys and/or agents are hereby appointed to prosecute and transact all business in the Patent and Trademark Office connected therewith.

Mary P. Bauman

Michael D. Alexander

Registration No. 31,926

Reg. No. 36,080

SEND CORRESPONDENCE TO:

DIRECT TELEPHONE CALLS TO:

Mary P. Bauman

(610) 889-6338

Sanofi Pharmaceuticals, Inc.

DIRECT FAXES TO:

Patent Department

9 Great Valley Parkway

(610) 889-8799

P.O. Box 3026

Malvern, PA 19355

Sanofi

32-34 rue Marbeuf

75008 Paris, FRANCE

DN 80111 - 2 -

ASSIGNMENT TO SANOFI RECORDED IN U.S. PATENT AND TRADEMARK OFFICE ON FEBRUARY 11, 1992 AT REEL 6011, FRAMES 615 AND 616;

CHANGE OF NAME FROM SANOFI TO ELF SANOFI RECORDED IN U.S. PATENT AND TRADEMARK OFFICE ON JUNE 22, 1993 AT REEL 6583, FRAMES 399-403; AND

CHANGE OF NAME FROM ELF SANOFI TO SANOFI RECORDED IN U.S. PATENT AND TRADEMARK OFFICE ON JUY 22, 1997 AT REEL 8613, FRAMES 0145-0149.

ASSIGNEE CERTIFICATION

Attached to this power is a "CERTIFICATE UNDER 37 CFR 3.73(b)."

SANOFI

Dated:

12 NOV 97

By:

JOHN M. SPINNATO

Attorney-in-Fact

(authorization attached)

Encl.: As listed above

Docket No. 80111 PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent of .: Claude Bernhart et al. I hereby certify that this correspondence is

being deposited on the date indicated below with the United States Postal Service as first

Patent No.: 5,270,317 class mail addressed to:

Assistant Commissioner for Patents,

Washington, D.C. 20231

December 14, 1993

Serial No.: 07/794,497

Filing Date: November 20, 1991

FOR: N-SUBSTITUTED HETEROCYCLIC DERIVATIVES.

THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS IN WHICH THEY ARE PRESENT

CERTIFICATE UNDER 37 CFR 3.73(b) ESTABLISHING RIGHT OF ASSIGNEE TO TAKE ACTION

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Grant Date:

1. The assignee of the entire right, title and interest hereby seeks to take action in the PTO in this matter.

IDENTIFICATION OF ASSIGNEE

2. Sanofi

A Société Anonyme of France

PERSON AUTHORIZED TO SIGN

3. John M. Spinnato

Attorney-in-fact (authorization attached)

I, the person signing below, aver that I am empowered to sign this statement on behalf of the assignee.

BASIS OF ASSIGNEE'S INTEREST

Ownership by the assignee is established as follows:

A chain of title from the inventors to the current assignee as shown below:

- 1. As assignment from the inventors, Claude Bernhart, Jean-Claude Breliere, Jacques Clement, Dino Nisato, Pierre Perreault, Claude Muneaux and Yvette Muneaux to Sanofi as recorded in the PTO at Reel 6011, Frames 615-616 on February 11, 1992;
- 2. A change of name from Sanofi to Elf Sanofi as recorded in the PTO on June 22, 1993 at Reel 6583, Frames 399-403; and
- 3. A change of name from Elf Sanofi to Sanofi as recorded in the PTO on July 22, 1997 at Reel 8613, Frames 0145-0149.

COPIES OF DOCUMENTS IN CHAIN OF TITLE

Copies of the assignment and recordation of name change in the chain of title are attached as follows:

- 1. Assignment from inventors to Sanofi;
- 2. Change of name from Sanofi to Elf Sanofi; and
- 3. Change of name from Elf Sanofi to Sanofi.

DECLARATIONS

I, the undersigned, have reviewed all the documents in the chain of title of the patent matter identified above, and, to the best of my knowledge and belief, title is in the assignee identified above.

I hereby declare that all statements made herein of my own knowledge are true, and that all statement made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 12 NOV 97

ØHN M. SPINNÅTC

Attorney-in-fact

(authorization attached)

Encl.: As listed above



CASH ORDER FORM
(For Counter Use Only)

U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

 TR	110	T1/	

- 1. Check appropriate boxes and enter amount of remittance and dete.
- 2. Identify items or services desired.
- 3. Fill in name and address at bottom of form and sign.

TYPE OF SERVICE	REMITTANCE		DELIVERY	DATE
	, 40.00			
COPY OF RECORDS			- WILL CALL	Feb. 11, 1992
TO PECORDING DOCUMENTS	CASH CHECK			1 60. 11, 1332
DRAFTING	MONEY ORDE	B	X PLEASE MAIL	
			<u> </u>	
DO NOT USE THIS SPACE - OFFICE	USE ONLY			
DESCRIPTION OF ITEMS OR SERVI	CES TO BE FURNISHED:			·. , , , , , , , , , , , , , , , , , , ,
Please record the atta	ched ASSIGNMENT:			3 3 22 -
		T - 4 - 1		20
In re Application of:	Claude BERNHAR	i et al.		
Serial Number:	07/794,497		·	
Filed:	November 20, 199			: 3
For:	N-Sbustituted Hete	erocyclic De	erivatives	<u></u>
In favor of:	SANOFI			
Please return to the u	ndersioned after rec	cerdation.		
riease return to the a				
			1 501 40,00 CK	
NAME 060 MC 02/19/5 Richard E. Fichter	72 07794497		SIGNATURE	
BACON & THOMAS				
625 Slaters Lane - For	ırth Floor		Pichard E	Field
CITY	STATE	ZIP CODE	Richard E. Ficht	
Alexandria	Virginia	22314	Registration No. 2	

USCOMM-DC 63835-27

Full name of Inventor(s)

BERNHART Claude, BRELIERE Jean-Claude, CLEMENT Jacques, NISATO Dino,

PERREAUT Pierre, MUNEAUX Claude, MUNEAUX Yvette

hereby sell(s), assign(s) and transfer(s) to Société Anonyme : SANOFI

Full name and address of Assignee(s)

a French corporation duly organized under the laws of France

residing at : 40, Avenue George V

75008 PARIS (FRANCE)

[hereinafter called the Assignee(s)] the entire right, title and interest in and to any and all improvements which are disclosed in the application for United States Letters Patent entitled

Title of Invention

N-substituted heterocyclic derivatives, their preparation and the

pharmaceutical compositions in which they are present which was filed by the undersigned in the form of an International Application which designated the United States of America under Number PCT/FR91/00224 on <u>March 20, 1991</u> entered the National Stage in the United States of America under Serial Number 07/794 497 on November 20, 1991; the aforesaid application for United States Letters Patent and all divisionals, continuations and substitutes thereof; and any and all United States Letters Patent which may be granted therefor and any and all extensions, reissues or renewals thereof; and the right to all benefits under the International on Convention for the Protection of Industrial Property and under the Patent Cooperation Treaty.

It is hereby authorized and requested that the Commissioner of Patents issue any and all of said Letters Patent, when granted, to said Assignee(s).

Further, it is agreed that, when requested, without charge to but at the expense of said Assignee(s), the undersigned will execute all divisional, continuing, substitute, renewal and reissue patent applications; execute all rightful other papers; and generally do everything possible which said Assignee(s) shall consider desirable for aiding in securing and maintaining proper patent protection.

Signed at PARIS

MUNEAUX Yvette

Date

this third day of February

, 19 92 .

Full

signature(s)

Inventor(s)

INVENTOR(S): EERNHART Claude Bendent Claude Breliere Jean-Claude Brelieve Landlande

CLEMENT Jacques Chinest Joseph NISATO Dino Dino Minal 3


PERREAUT Pierre Perreaut Reme MUNEAUX Claude Muneauxe Claude

Full Signatures of Witnesses

Muneuux Yvette

RECORDED PATENT AND TRADEMARK CEFICE

-FEB || man



U.S. Department of Commerce Patent and Trademark Office

RECORDATION FORM COVER SHEET

PATE	NTS ONLY
To the Honorable Commissioner of Patents and Trademarks.	Please record the attached original documents or copy thereof.
1. Name of Conveying Partylies):	2. Name and Address of Receiving Partylies):
SANOFI	Name: ELF SANOFI
	Internal Address:
	Street Address: 32/34, Rue Marbeuf
☐ Additional names of conveying parties attached.	City, State, Zip: 75008 Paris, France
3. Nature of Conveyance:	City, State, 24. 75000 rails, France
☐ Assignment ☐ Merger ☐ Security Agreement 25 Change of Name	
Other:	☐ Additional name(s) and address(es) attached.
Execution Date: January 31, 1992	
(4.)(A) Patent Application Number(s):	4. (B) Patent Number(s):
07/794,497	11
	*
	14
If this document is being filed together with a new	
application, the execution date of the application is:	
	W.S. Tatel Number of Amiliantian and Patenta Invalid
5. Name and Address of Party to whom Correspondence Concerning this Document Should be Mailed:	6) Total Number of Applications and Patents Involved:
Name: Richard E. Fichter, Registration No. 26,382	7) Total Fee:
Address: Becon & Thomas	(137 CFR 3.41) \$40.00
625 Slaters Lane - 4th Floor Alexandria, Va 22314	
	☐ Enclosed. ☐ Authorized to be charged to deposit account.
	(8) Deposit Account Number:
	02-0200 ATTACH DUPLICATE COPY OF THIS PAGE F PAYING BY DEPOSIT ACCOUNT.
DO NOT	
070 MG 07/02/93/07794497	1 581 40.00 CK 91682815
9. Statement and Signature: To the heat of my knowledge and helief the	e foregoing is true and correct and any attached
copy is a true copy of the original documen	
P. O.	$\alpha = 0$
Richard E. Fichter Name of Person Signing	Signature June 22, 1993 Date
	.)
(/ 4	Total number of pages comprising cover sheet: $\mathcal{X} S = \mathcal{K}$

SANOFI

has become:

ELF SANOFI

Joint Stock Company

with a capital of FF. 1 845 855 200

Registered Office:

40, Avenue George V

75008 PARIS

transferred to:

32/34, Rue Marbeuf

75008 PARIS

T.C.R. PARIS B 772 059 332

Upon the end of the meeting dated January 31, 1992, the mixed General Meeting of the shareholders has decided:

In its ordinary part:

- to appoint as director, for a period of 4 years, STERLING WINTHROP INC., company under American law recorded in the State of Delaware, with registered office, 90 Park Avenue, NEW YORK, NY 10016 (USA), represented by Mr. Louis MATTIS, domicilied 90 Park Avenue, NEW YORK, NY 10016 (USA).

His mandate shall expire at the end of the General Meeting which will be called upon to judge the accounts of the 1995 fiscal

year.

In its extraordinary part:

- to adopt for the company the denomination

ELF SANOFI

- to amend Article 2 of the company's articles of incorporation accordingly:

previous wording: the company's denomination is SANOFI New wording: the company's denomination is ELF SANOFI

- to transfer the registered office to:

32-34, Rue Marbeuf 75008 PARIS

- to amend section 1 of Article 4 of the articles of incorporation accordingly:

Previous wording:

The registered office is in PARIS 8th, 40 Avenue George V

New wording:

The registered office is in PARIS 8th, 32-34 Rue Marbeuf.

The rest of the article remains unchanged.

Mention shall be made to the T.C.R. of PARIS.

For opinion The Board of Directors

DECLARATION

I, Claudine L. Overton, translator to Cabinet BEAU DE LOMENIE, 158, rue de l'Université, 75340 - PARIS CEDEX 07, France, hereby declare that I am conversant with the English and French languages and that I am a competent translator thereof.

I also declare that, to the best of my knowledge and belief, the document attached hereto is a true translation of the accompanying Extract from the journal "Les Annonces de la Seine".

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knwoledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 101 of Title 18 of the United States Code and that such willfull false statements may jeopardize the validity of the Extract.

Signature of Translator

Claudine L. OVERTON

15th June 1993

Date

Photocopie, certifiée conforme 80 document

ierre RANVIER - Notaire FRANCAISE GAZETTE

FONDATEUR RENÉ TANCRÈDE

73° ANNÉE

JEUDI 13 FÉVRIER 1992 - N° 12 - 1,20 F

ENVIRONNEMENT

es sondages d'opinion le montrent, l'environnement est la deuxième préoccupation des Français après le chômage. Face aux implications économiques de cette aspiration, la Chambre de Commerce et d'Industrie de Paris mène une réflexion sur le rapport entre l'environnement et les entreprises. Le bilan qu'elle présente a pour avantage de sensibiliser sur les implications de ce rapport et de vulgariser les conclusions qu'elle apporte.

La C.C.I.P. constate que l'environnement représente pour les entreprises un champ d'expansion prometteur : les marchés européens de l'environnement devraient passer de 300 milliards de francs en 1987 à 500 milliards en 1993 et 700 milliards en l'an 2000. De plus, ils seront créateurs d'emplois.

L'environnement doit également être pris en compte lors des réflexions sur l'aménagement du territoire : une région qui s'en préoccupe est une région résolument tournée vers l'avenir car l'environnement est un facteur d'attractivité internationale. J.-R. T.

Rectificatif à l'éditorial du 16 janvier 1992 concernant les cessions d'actions

Puisqu'. I n'y a plus d'actions au porteur et que les titres sont, par voie de conséquence. dématérialisés, il est donc impossible de faire des dons manuels d'actions depuis le 2 janvier 1992 car la Loi de Finances pour 1992 alourdit le régime des dons manuels dans la mesure où l'Administration peut demander au donataire l'origine des fonds donnés et le taxer sur simple déclaration verbale.

JURISPRUDENCE CIVILE : Responsabilité civile professionnelle	2
POINT JURIDIQUE : Le régime Pons sous la loupe fiscale par Jean-Jacques Jugie	4
VIE DE L'ENTREPRISE : La CCIP : des chefs d'entreprise au service des entreprises	5
ANNONCES LÉGALES 9 à	21
DIRECT	24
VIE ACTUELLE : Le patrimoine des ménages par Jean-Jacques Jugie	25
AU FIL DES PAGES	26
CIVILISATION :	27

JOURNAL OFFICIEL D'ANNONCES JUDICIAIDES ET LÉGALES

REL6583

Bi-hebdomadaire: hundi-jeudi Siège social et administration

15, rue de Verneuil - 75007 PARIS D: 42.64.36.35 - Télex: 216 382 - Fex: 47.83.92.15

Bureaux:

- 4. rue de la Masse, 78910 BEHOUST Tél.: 34.87.25.63
- 1. place Paul-Verlaine, 92100 BOULOGNE Tél.: 46.94.66.00
- 67. rue Marcel-Dassault. 93140 BONDY Tél : 48 02 46 39
- I, place Charlemagn 94290 VILLENEUVE-LE-ROI, Tel.: 45.97.42.05

Copet social. Etude, recherche et tra-vaux d'ordre' scientifique, et technique, recherches en vue de faciliter le fonction nement ou le développement d'entrepri-ses existantes, ou la mise au point ou la préparation pour un stade d'exploitation ultérieur de tout projet d'affaire ou d'en-treprise industrielle, commerciale, finan-cière, agricole immobilière ou mobilière et toute négociation en vue de la réalisa-tion éventuelle de ce programme, l'obten-tion de toute concession et autorisation administrative. administrative

administrative.
Clause d'agrément:
Clause d'agrément:
Cession entre vifs: Parts non cessibles entre associés.
Cession aprèt décès.
En cas de décès de l'un des associés, donit de rachat de ses parts par les autres associés, dans un délai d'un mois.
Durde: 50 ans à compter de son immatriculation au R.C.S. sauf dissolution anticirée ou proprogration.

anticipée ou prorogation.

Gérance: Mademoiselle Isacelle CARON, demeurant 37, Rue Albert 75013

RON, demeurant 37, Rue Albert 75013 PARIS a été nommée gérante de la so-ciété pour une durée de 2 ans. Immatriculation : La société sera im-matriculée au R.C.S. de PARIS. 01948 Pour avis

Aux termes d'un acte sous seing privé en date à PARIS du 31 janvier 1992, il a été constitué une Société à Responsabili-té Limitée présentant les caractéristiques Dénomination :

CONSORTIUM **EUROPEEN HOTELIER**

Siège social : 58, Avenne d'Iènn 75116 PARIS

73110 PARKS
Capital social: 200 000 F. divisé en
1 000 parts de 200 F. chacune
Durée: 99 ans à compter de son immatriculation au R.C.S. sauf dissolution

anuaper ou prorogation.

Objet : Toutes opérations bôtelières, para-bôtelières, touristiques, mobilières et immobilières, commerciales et financières, le tout seul ou en participation avec d'autres sociétés sous quelque forme que ce soit. anticipée ou prorogation. Objet : Toutes opéri

que ce soit.
Gérance: Aux termes d'une décision collective en date du 31 janvier 1992.
Monsieur Nasr ABOU-DIWAN demeurant 6, Rue Dufrenoy 75016 PARIS a été désigné gérant pour une durée d'un an

Aux termes d'us acte sous seins procesil a tet constitué une Societé Repossibilité Limitée de type E.U.R.L. présentant les caracteristiques suivantes :

Dénomination sociale :

R.P. INVEST

Siège social : 27, Rue de Pleurus 75066 PARS Capital social : 50 000 F. divisé en 500 parts de 100 F. chacune, entièrement li-bérôes en numéraire.

la création de tous hôtels ou résiden-

· la réalisation de tous investissements directs on indirects dans les DOM-TOM dans le cadre des dispositions de la loi du 11 juillet 1986, et notamment dans le secteurs du Tourisme, de l'Hôtellerie et

du Transport.

- la commercialisation de toutes pres-

tations lides au Tourisme

- la réalisation de tous investissements
directs ou indirects dans des immeubles à

usage de bureaux
- la création ou l'exploitation directe
de centres d'affaires installés dans ces

- la réalisation de toutes transactions

- la prise de participations dans diver-ses sociétés

ses sociétés
les activités de photogravure, de publicité, d'imprimerie, de voyage, de maintenance, d'égaignements de bureaux, de télématique, d'entretien des bureaux la perception de toutes rémunérations commerciales

- l'exploitation directe ou indirecte de

 Fexploristion directe ou indirecte de biens appartenant à la société
 Tactivité de loueur en meublé et toutes activités annexes
 Durée : 99 ans à compter de son immatratistion au R.C.S. sauf dissolution autérielle en temperation. anticipée ou prorogation.

Gérance Monsieur Roger PODGUS-ZER demeurant 27, Rue de Fleurus 75006 PARIS a été nommé gérant pour une durée illumitée

Immatriculation : La société sera im-matriculée au R.C.S de PARIS. Pour avis

MODIFICATION

ASSISTANCE SURVEILLANCE RADIOSECURITE

ASR

Societic Anonyme au capital de 256 000 F Siège Social: 2, Rue Plichon 75011 PARIS R.C.S. PARIS B 303 447 619

Aux termes du procès-verbal de l'As-semblée Générale Extraordinaire en date du 3 février 1992, les actionnaires ont

pris acte de la démission avec effet au 31 décembre 1991 de leurs fonctions d'Administrateur de : Mademoiselle Béatrice FISCHER,

Monsieur Pierre BRAC, Monsieur André KURFUST.

Monsieur André KURFUST.
décidé de nommer en qualité d'Administrateur. Monsieur Robert MOISY,
demeurant 19. Avenue Liègeard 93270
SEVRAN.
décidé d'étendre l'objet social à toute
forme d'activité sécuritaire et nouamment

au contrôle d'accès, prestations de têlé-surveillance, vidéo-surveillance ou pro-tection des biens contre le vol et l'effraction. L'article 2 des statuts a été modifié en

conséquence.

décidé de modifier la dénomination sociale, à compter du 1^{er} janvier 1992 :
Nouvelle dénomination :

ASSISTANCE SECURITE RISK - ENGINEERING A.S.R.

L'article 3 des statuts a été modifié en

conséquence.

Au termes du procès-verbal du Conseil d'Administration en date du 3 février
1992, les Administrateurs ont décide de
nommer en qualité de Président du Conseil d'Administration, Monsieur Gilles
COULON, demeurant 5 Terrasse des
Reflets 92400 COURBEVOIE.

Mention en sera faite au R.C.S. de
PARIS

JUN 22 1993 Steps social: 5, 8 top Latter 75009 PARIS R.C.S. PARIS D 347 748 436

D'une Assemblée Générale Extraordinaire en date du 31 janvier 1992, il ré-

naure en date en el parver 1772, il re-salte que:

le capital social a été porté de la somme de 2 000 F à la somme de 402 000 F par voie d'apport d'une somme de 400 000 F en numéraire les articles 6 et 7 des statuts ont été modifiés en conséquence.

modulés en conséquence.

Mention en sera faite au R.C.S. de PARIS.

01828

CHAUSSURES ANDRE

Societé Anonyme au capital de 339 240 850 F Siège Social : 28, res de Plandre 75819 PARIS R.C.S. PARIS B 308 449 024

Aux termes de l'Assemblée Générale Mixte du 28 janvier 1992, il a été déci-

de .
de nommer en qualité de Commissaire aux comptes titulaire la société SEFI-GEST, sise 36, Rue de Courcelles 75008 PARIS, R.C.S. PARIS 70 B 1055, en remplacement de Monsieur Étienne CABBE

remplacement de Monsieur Etienne CARRE. de modufier la dénomination sociale qui devient :

GOOUPE ANDRE S.A.

L'article 2 des statuts a été modifié en

SOCIETE POUR LA COORDINATION D'ETUDES ET DE REALISATIONS TECHNIQUES ECONOMIQUES ET SOCIALES CERTES

Societé a Responsabilité Limitée au capital de 50 000 F Siège social : 35, Rue du Pout Neuf 75001 PARIS R.C.S. PARIS B 304 801 350

Par délibération de l'Assemblée Géti-rale Extraordinaire du 31 janvier 1992, les associés ont décidé de changer, à compter de cette date, la dénomination sociale en adoptant celle de :

BUSINEST FUSIONS ACQUISITIONS C.E.R.T.E.S. - B.F.A.

Les statuts ont été modifiés en conséquence.

Mention en sera faite au R.C.S. de

> SANOFI **ELF SANOFI**

Societé Anonyme au capital de 1 845 855 200 F Siège social : 40. Avenue George V 75008 PARIS transféré au : 32/34, Rue Marbeuf 75008 PARIS R.C.S. PARIS B 772 059 332

Aux termes de sa séance en date du 31 janvier 1992. l'Assemblée Générale miate des actionnaires a décidé:

Dans sa partie ordinaire:

de nommer en qualité d'administrateur, pour une période de 4 ans, STER-LING WINTHROP INC., société de droit américain immatriculée dans l'Etat du Delaware, avant son siège social, 90, du Delaware, ayant son siège social, 90, Park Avenue NEW YORK, NY 10016

rara Avenue NEW YURK, NY 10016 (USA), représentée par Monsieur Louis MATTIS, demeurant 90, Park Avenue NEW YORK, NY 10016 (USA). Son mandat viendra à expiration à l'is-sue de l'Assemblée Générale appelée à statuer sur les comptes de l'exercice 1995.

Dans sa partie extraordinaire : d'adopter pour la société la dénomi-

ELF SANOFI

de modifier en conséquence l'article oe mouser en consequence l'article 2 des status:
Ancienne rédaction : la société a pour dénomination : SANOFI
Nouvelle rédaction : la société a pour dénomination : ELF SANOFI
de transfèrer le siège social au :
32-34, rue Marteur / 5808 PARIS
de modifier en conséquence l'atinéa l
de l'article 4 des statuts :
Ancienne rédaction
Le siège social est à PARIS 8ème, 40,
Avenue George V
Nouvelle rédaction :
Le siège social est à PARIS 8ème,
32-34, Rue Marbeuf.
Le reste de l'article est sans changement.

Mention en sera faite au R.C.S. de

UISIS

Le Comeil d'Administration

PHOTO 4

Société à Responsabilité Limitée au capital de 50 000 F Siège Social : 34, Boulevard Haustmann 75008 PARIS R.C.S PARIS B 383 352 093

Aux termes d'un procès verbal de la réunion de l'Assemblée Générale Extra-ordinaire en date du 31 Janvier 1992, les associés ont décidé de modifier la dénomination sociale par

SERVICES & MARKETING

En conséquence, l'article 3 des statuts a été modifié Mention en sera faite au R.C.S. de PARIS
001969

GROUPE PIERRE BATON DIFFUSION PROMOTION IMMOBILIERE

Société Anonyme au capital de 1 000 000 F Siège social: 21/23, Avenue Paul Donne 75016 PARIS R C.S. PARIS B 602 051 930 60 B 5193

Le Conseil d'Administration dans sa séance du 31 décembre 1991 a accepte la démission de la société PIERRE BA-TON PARTICIPATION, de ses fonc-

Pour avis Le Conseil d'Administration. 01940

PSYNERGIE PARIS

Société à Responsabilité Limitée au capital de 50 000 F Siège Social : 1, Senare de Luynes 75007 PARIS

R.C.S. PARIS B 381 632 934 91 B 5751

L'Assemblée Générale Ordinaire des associés réunie extraordinairement le 31 janvier 1992 :

panvier 1992:
a pris acte de la démission de Mon-sieur François HUMBLOT de sea fonc-tions de Gérant à compter du 1^{er} février 1992,

1992.

a nommé en qualité de Gérante à compter du 1^{er} février 1992 et pour une durée d'une année tacitement reconductible, Madame Anne-Marie PASQUET PAOLI, derneurant 48, Rue du Capitaine Ferber 75020 PARIS.

Dépot R.C.S. de PARIS.

1898 Pour avis

SOCIETE FINANCIERE D'INVESTISSEMENT EN OEUVRES D'ART - ART - CITE

A Directoire et
A Directoire et
Conseil de Surveillance
au capital de 3 000 000 F.
Siège Social:
12, Avenue Mattenas
75008 PARIS
R C.S. PARIS B 328 848 205

Aux termes du procès-verbal de la réu-nion du Conseil de Surveillance en date du 22 janvier 1992, il a été pris acte de la démission :

a demission :

- de Monsieur Gaston RECIPON de es fonctions de membre et Président du

Directoire.

de Monsieur Jean-Pierre BLANC de ses fonctions de membre du Conseil de

ses ionctions de memore du Conseir de Surveillance. Le Conseil de Surveillance a nommé Monsieur Jean-Pierre BLANC aux fonc-tions de membre du Directoire et Prési-dent du Directoire en remplacement de Monsieur Gaston RECIPON. Mention en sera faite au R.C.S. de 2015.

Le Conseil de Surveillance 01853

Maître Gérard LAGEDAMONT Avocat à la Cour Immeuble Kennody Conseil 2. Boulevard Kennody 66100 PERPIGNAN

TROPIC ATOLL S.A.

Société Anonyme au capital de 250 000 F Siège Social: 95, Rue La Bolt 75006 PARES R.C.S. PARIS B 339 149 759

FRAMEL L'Assemblée Générale des actionna res réunie le 28 mars 1990, a désigné de qualité de Commissaire aux comptes suppléant, Monsieur René SAINT GER-MES, Expert Compuble, demeurant 70. Avenue Guynemer 66000 PERPI-GNAN.

Montieur Bernard FOURCADE, Ex-Monsieur Bernard FOURCADE, Ex-pert comptable, demeurant 1, Avenue Jean Gicno 66000 PERPIGNAN, étant devenu Commissaire aux comptes titulai-re, en remplacement de Monsieur Daniel RUIZ. Expert Comptable, demeurant 26, Rue du Fournas 66240 SAINT ES-TEVE, demissionnaire:

Deux sopies de ladite délibération se-ront dépusées au Greffe du Tribunal de Commerce de PARIS.

Le Conseil d'Administration

S വ

 ∞

ယ

08-01-1997

B/O FORM PTO-1595 (1/31/92)	10050	0968	RECEIVED Department of Commerce
	-	ORM COVER SHEET	JUL 22 1997
		TS ONLY	_ ** *
			RECEIPT ACCIONS
To the Honorable Commissioner of Patents a			
1. Name of Conveying Party:	Mon	2. Name and Addre	ess of Receiving Partylies):
ELF SANOFI	7.2	Name:	SANOFI
	22.9.	2. Name and Addra Name: Internal Address: Street Address:	
		Street Address:	32-34 rue Marbeuf
☐ Additional names of conveying partic	es attached.		75000 Baria France
3. Nature of Conveyance:		City, State, Zip:	75008 Paris, France
☐ Assignment ☐ Me	erger nange of Name		
Other:	•		nal name(s) and address(es) attached.
Effective Date: June 1, 1994		L) Additio	na namats) and additional account.
4. (A) Patent Application Number(s):		4. (B) Patent Numb	per(s):
		5,270,3	317
		5,352,7	788
		5,166,4	116
		5,290,9	
		4,945,0	
If this document is being filed together with	a new	5,279,9	
application, the execution date of the application	ชนิดการ:	5,284,7	
	☐ Additional (Numbers Attached.	
5. Name and Address of Party to whom Cor		6. Total Number of	Applications and Patents Involved:
Concerning this Document Should be Mailed	<i>t:</i>		7
Name: Terri J. Latonik, Registration No. 3	6,577	7. Total Fee:	
Address: Bacon & Thomas		(37 CFR 3.41)	\$280.00
625 Slaters Lane - 4th Floo	r		
Alexandria, Va 22314		26 Enclosed.	hand a day all any are
			s charged to deposit account.
		8. Deposit Accoun	02-0200
		ATTACH DUPLE	CATE COPY OF THES PAGE & PAYING BY DISPOSIT ACCOUNT.
	DO NOT U	SE THIS SPACE	
9. Statement and Signature:			
			and correct and any attached
copy is a true copy of the on	iginal document.		
Terri J. Letonik	Tends	atomik	July 22, 1997
Name of Person Signing	- /	Signature	Date
		Total number of	pages including cover sheet: 5

08/01/1997 TTOM11 00000112 5270317 01 FC:581 280.00 DP

DECLARATION

I, Claudine L. Overton, translator to CABINET BEAU DE LOMENIE, 158, rue de l'Université, 75340 – PARIS CEDEX 07, France, hereby declare that I am conversant with the English and French Languages and that I am a competent translator thereof.

I also declare that, to the best of my knowledge and belief, the document attached hereto is a true translation of the accompanying Extract from the journal "Les Petites Affiches".

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that all these statements were made with the knowledge that willfull false statements and the like so made are punishable by fine or imprisonment, or both, under Section 101 or Title 18 of the United States Code and that such willfull false statements may jeopardize the validity of the Extract.

Signature of translator	plane.
Signature of timestation	Claudine L. OVERTON
	November 30, 1994
Date	######################################

114939 - "Petites Affiches"

SANOFI
(formerly ELF SANOFI)
A joint stock company
with a capital of FF. 2 208 967 500
Registered Office:
32-34 rue Marbeuf
75008 PARIS
T.C.R. Paris B 732 059 332

1. On June, the first, nineteen ninety four,

The regular General Meeting appointed as director for a period of four years, i.e. up to the date of the meeting which will be called upon to judge the accounts of the nineteen ninety seven fiscal year, Mr Philippe HUSTACHE, domiciled 31, rue Anna-Jacquin, 92100 Boulogne.

II. On June, the first, nineteen ninety four,

The Extraordinary General Meeting decided to change the company's denomination and to amend consequently Article 2 of the company's articles:

Former wording
the company's denomination is ELF SANOFI
New wording
the company's denomination is SANOFI

Mention thereof shall be made to the Trade and Companies Register of Paris.

For notification, The Board of Directors

Sommaire - 2 CAHIER

	PARIS	Hts-de- Sein e	Seine St-Denis	Val-de- Marne
Adjudications	25			
Sociétés	26	34	52	53
Avis aux actionnaires	35	49	53	54
Avis financiers		-		
Oppositions	43	51	53	
Avis divers				55
Informations du Tribunal de comme	rce			_
Tableau des ventes de fonds de con	nmerce			58

Calendrier des parutions

Ce tableau est seutement donné à titre indicatif pour la remise des copies. Le journal ne porte que la dernière des dates figurant sur ce tableau.

JUIN

MARDI 7 Nº 68 - MERCREDI 8
Les annonces seront reques jusqu'au mardi à 17 heures.

JEUDI 9 Nº 69 - VENDREDI 10

Les annonces seront reçues jusqu'au jeudi à 17 heures.

SAMEDI 11 - DIMANCHE 12 Nº 70 - LUNDI 13

Les annonces seront reçues jusqu'au vendredi à 17 heures

MARDI 14 Nº 71 - MERCREDI 15

Les annonces seront reçues jusqu'au mardi à 17 heures.

Avis important

Par arrêté de : 1° M. le préfet de Paris, du 2° décembre 1993 : 2° M. le Prefet des Hauts-de-Seine, du 22 décembre 1993 : 3° M. le Prefet de la Seine-Saint-Denis, du 30 décembre 1993 : 4° M. le Préfet du Val-de-Marne, du 27 décembre 1993.

Les journaux LES PETITES-AFFICHES - LA LOI

ant ete designes comme publicateurs officiels pour recevoir, en 1994, cans les départements de Paris, des Hauts-de Seine, de la Seine-Saint-Denis et du Val-de-Marine, toutes annonces judiciaires et légales en matière de procédure diville et de commerce, ainsi que des actes de sociétés.

N.B. — L'administration décline toute responsabilité quant à la teneur ces annonces légales.

TARIF DE PUBLICITE. — Annonces legales 75 24,53 F la ligne + T.V.A., 92 : 24,47 F la ligne + T.V.A., 93 : 24 53 F la ligne + T.V.A. et 94 : 24,45 F la ligne + T.V.A.

Avis financiers: 45,00 F la ligne + T,V A -- Avis divers: 40,00 F la ligne + T V,A;

ADJUDICATIONS

115104 - Petites-Affiches

Cabine: de Maître LEMOINE FANTIJZ Avocat

au Barreau de PARIS 43, rue Remy-Oumoncei 75014 PARIS Tel: 42 18 18 80 C 139-)

VENTE PAR SUITE DE SURENCHERE

Il sera procede le Jeudl 23 Juin 1994 à 14 h 30, en l'audience des criess du Tribunal de Grande instance de PARIS, seant au PALAIS DE L'USTICE à PARIS, à l'adjudication au plus offrant et dernier encherisseur en 2 lots des immeubles dont la designation suit.

- 5, rue des Petits-Hôtels 75010

- 1" LOT, au 3" etage, APPARTEMENT de 2 pieces et 1 cava en sous-sol,

- 2º LCT, au 3º etage. APPARTEMENT de 2 pièces et 1 cave en sous-sol.

Cas immediates ont ete saisis à la requete de l'UNION DE CREDIT J'OUR LE BATIMENT due UIC BIS à la capitat 1,674 929 200 F, PICS PARIS BISSO 04 624. Siège Social S, Avenue Kleber, 75016 PARIS, agissant en la personne de son PIC G inomichie audit siège. AYANT POUR AVOCAT Maitre LEOPOLD COUTURIER AVOCAT MAITRE AVOCAT MAITRE LEOPOLD COUTURIER AVOCAT MAITRE AVOCAT MAITRE LEOPOLD COUTURIER AVOCAT MAITRE MAI

— Iff Lot 1211 000 Filen sis designarges

= 2° Lot 201 000 F en sus des charges rar jugement de l'audience des Sassies dudit Tribunal, en date du 24 Mars 1994.

Une surenchère du dixième a été formée pour ces 2 lots, par Madame Marlène LEVY, demeurant 93, rue de la République, 92800 PUTEAUX, suivent acts du greffe en date du 5 Avril 1994, dénoncee par acte d'avocat à avocat en date du 8 Avril 1994 à

- Maître POULAIN, Avocat de Monsieur DEBAN Adjudicataire;
- 2. Maître LEOPOLD COUTURIER, Avocat σε LU.C.B. poursuivante ;
- 3. Maitre GARNIER CHALE, Avocat de la SCJI. MC MAYA, partie saisse, siège social : 5, Rue des Petits-Hôtels, 75010 PARIS, RC.S. PARIS D 343 292 587. Capital 20.000 F.

En consequence, il sera procèdè à la nouvelle adjudication desdits inimeubles sur la mise à prix de :

- 1" Lot : 232,100 F.
- 2º Lot : 221,100 F.

On ne peut porter des enchères qu'en s'adressant à l'un des Avocats exerçant près le Tribunal de Grande Instance de PARIS.

Fait et rédigé à PARIS le 3 Juin 1994

Par l'Avocat poursuivant soussigne s'adresser pour tous renseignements à :

Maitre Beatrice LEOPOLD-COUTU-RIER, Avocat au Barreau de PARIS, 12, rue Théodule-Ribot, 75017 PARIS, 781, 47,56,59,89, R. 291, Avocat de LUCB, dépositaire d'une copie du canier les charges.

Maitre LEMOINE FANTUZ, 43, rue Remy-Cumoncel, 75014 PARIS, Tai, 42 18.18 80, C 1390, Avocat du poursuivant.

Au Grette des Criees du Tribunal de Grande Instance de PARIS PALAIS DE JUSTICE PARIS où le cahier des charges est dénose

Facilitez vos recherches

CONSULTEZ NOTRE BANQUE DE DONNÉES ANNONCES LÉGALES

MINITEL 3617 CODE JAL

The second control of the second seco

LES PETITES-AFFICHES: 2, RUE MONTESQUIEU - 75001 PARIS - TEL. 42.61.56.14 - 42.61.56.15 - FAX. 47.03.92.02

1 4 1 01 - 50 OUAL DES ORFEVRES - 75001 PARIS - TEL 43.25-54.45 N. FAX. 46.34.19.70

REEL: 8613 FRAME: 0148

Societé anont me au capital de July (un l Siège social 17 bis, boulevard Haussmann 75009 PARIS

P.C.S. Faris 8 330 149 030

Suivant procés-verbat de l'assemblée genérale ordinaire en date du trente juin mil neut cent quatre-vingt-reut,

Il a été pris acte de la demission de la société UNION FINANCIERE FONCIERE ET COMMERCIALE UFICO, représentée par Madame Edith CROS de ses loncitions d'administrateur Madame Edith suit CROS ayant eté nomme administrateur à La

Suivant procés-verbal de l'assemblée générale ordinaire en date du vingli-cing juin mil neut cent quatre-vingt-onze.

Le cabinet RICHARD ET ASSOCIES, dont le siège social est 7, avenue de Friedland, Paris (buitième arrondisse-ment), a eté nomme en qualité de commissaire aux comptes suppleant

Suivant processiernal de l'assombles generale ordinaire en date du trente juin mil neuf cent quatre-vingt-treize

Il a été pris acte du non-renouveilement de mandat d'administrateur de Monsieur Patrice DANO, Monsieur Charles ABEILLE, demeurant 38, avenue de Sulfren, Paris (quinzième arrondissementi, et la société BANQUE TRANSA-FLANTIQUE, dont le siège est 17, pouleard Haussmann, Paris (neuvième priondissementi, represente par Monsieur Nordert GOMAR demeurant 33, avenue Paul-Doumer, 75116 Paris, prit ete nom-

ADOL: LEGIZE

dissolution anticipee de la societe mai-gré que les capitaux propres soient devenus inférieurs à la moitie du capitai

Mentions seront portees au registre du commerce et des societes de

114939 - Petites-Affiches

SANOFI

(anciennement ELF SANOFI)

Société anonyme capital de 2 238 967 530 F Siègis social

32-34, rue Merbeuf 75008 PARIS

P.C.S. Paris B 722 759 232

I. En date du premier juin mit neut

L'assembler generale ordinaire à comme aux fonctions d'administrateur (GERER PARTICIPATION Madame ruis de à societé pour les mettre en qu'à la date de l'assembler appeire à Pablo-Picasso, 3200 Nanteire en remiscables aix societes immobilières mensil cent quatre-singli-dix-sept. Mon-l'appoint de Monsieur ASCHEN.

décide de changer la denomination lociale et de modifier en consequence l'article 2 des s'atuls

Ancienne reduction

La societé a pour dénomination EEF SANOFI

Nouvelle reduction

La société a pour tenon intion

SANOFI

Mention en tora la le au registra du commerce et des societes de

Pour avis LE CONSEIL D'ADMINISTRATION

114838 - Pentes-Affiches

SOCIETE DE GESTION MONT CANISY

audiete à responsabilité i mitée au capital de 50,000 F Sièce social

66, avenue des Champs-Elysées 75008 PARIS

P C S Paris 8 293 425 395

Par décision de l'assemblée générale cent quatre-vingt-quatorze

Carticle 2 des statuts de la societé n responsabilité limitée Société de Gestion to Mont Canisy est modifie comme

La société a po-

 L'organisation de seminaires ongrés et manifestations d'ordre scientifique, culturel, sportif, etc...

A ces fins, la possibilité de proceder l des locations de toute nature pour reali-ser dans les meilleures conditions les manifestations di-dessus. En particulier, manuestations processes on periodicing to do do de de consideration processes et sans que l'enumeration chaptes soil forme de sociétés civiles realisant des limitative possibilité de louer des instal-l'opérations à finalité l'occtive prevues à l'attons immubilieres uiverses, ensembles : l'article H, 313-17, immobiliers, terrains, domaines, salles de conference, des moyens de transports terrestres, maritimes ou aériens

— foute prise ou retrocession de par-licipation dans le capital de toute entreprise, association ou groupement a caractère civil, commercial, industriel ou financier, de nationable française ou:

— Elle pourra agir, directement pui societé, indirectement pour son compte ou pour i. L' més administrateurs le compte de tiers et soil seule, soit en la Sulvant procés-verbal de l'assemblée association, participation ou societé generale extraordinaire en gale 39 avec toutes autres societés ou personvingtists octobre mil neul cent quatre . Des et realiser directement ou indirectement, un France atou à l'etranger, sous il a els décidé de ne pas prononcer la usualue forme que ce soit, les opera-ssolution anticipee de la societe mai-à que les capitaus propres scient. Prendre, sous foules formes, fous intertes ou entreprises, françaises ou etran-gères, ayant un objet similaire ou de nature à developper ses propres attaires

115002 - Petites-Affiches

GERER CONSEIL

Societé ancryme au capital de 5 000 000 F

Siege social 41, avenue George-V 75008 PARIS

R.C.S. Paris B 378 817 605

Suivant proces-verbal en late du seize ars mil neuf cent quatre-vingt-quatorse.

Le conseil d'administration à nomme

CIES frommissaire aux comptes titu-taires, il convient de porter, en qualité de touveau commissaire aux comples tique raire in societe ERNST AND YOUNG DEPARTMENT DINSO D., it boulevard i Taussmann Paris ineuviema arrondisse (COST/e Ocietes Faris B 344 368 315

On ta humination de Monsieur Patricka parts De 18 injunitation de Monsieur Patrick | parts 300 - 816 préalablement autorisée 30UNELLE demeurant 34 bouveraire part 5 light de délibérant compétent de la néulaismann Paris fineuvième arrondissements en 2006 préalablement de la commissaire aux competent de la commissaire aux commissaire aux déponde au registre du commerce et déponde au régistre du commerce et des sinciétés de Paris

Modification sera taile au registre du commerce et des sociétés de Paris.

:15090 - Petites-Affiches

SCI DU 20 BIS RUE DE BEZONS

Societe civile immobiliere iu capital de 1 800,000 F Siège social :

14-16, rue Montellvet 75008 PARIS RCS Paris 0 322 687 757

Par décision de Fasseniuse gui neuf generale extraordinaire du vingt-cinq extraordinaire du vingt-cinq mai mil neuf generale extraordinaire du vingt-cinq ent quatre-vingt-quatorze mars nul neuf cent quatre-vingt-qua-Suivant procés-verbal de l'assemblée extraordinaire du vingt-cinq torze.

Il a éte décide

— De transferer le siège social au 117-119, quai de Valmy, PARIS (dixième arrondissement) et de modifier en consequence l'article 4 des statuts.

- De compléter et/ou modifier les statuts de la société pour les mettre en conformité avec les clauses types appli cables aux sociétés immobilières men tionnees au 2º du i de l'article R. 313-31 du code de la construction qui ont pris ta

De ces statuts modifiés ou complètés il est extrait

Objet. L'objet exclusif de la société est la réalisation d'opérations à finalité locative prevues au im du l'et au il de l'article 4, 313-17 du code de la construction at de l'habitation.

Cession des parts : Toute cession de etrangere, ainsi que la gestion et l'admi-i parts doit être présistlement autorisée nistration de ces participations : par l'organe délibérant compétent de la

L'inscription modificative sera déposée au registre du commerce et des sociétés de Paris.

Pour extrait. La gerante : AIPAL LA HENIN,

115093 - Pethes-Affiches

SCI

MONTREUIL LES OSERAIES

Sociáté civile immobilière au capital de 8.050.000 F Siège social :

14-16, rue Montalivet 75008 PARIS

R.C.S. Paris D 322 687 740

Suivani proces-verbai de l'assemblee générale mixte du vingt octobre mit neuf cent quatre-vingt-treize

Il a été décide

De transférer le 117-119, quai de Vaimy, PARIS (dixième arrondissement), et de modifier en consequence l'article 4 des statuts.

Statuer sur les comptes de l'exercice mil clacement de Mornieur du code : e la construction qui ent priorité de PROICH Yorks.

Suite 3 une lusion-absorbtion part forme de sociétés civiles réalisant des l'article Proposition du code : e la construction qui ent priorité de PROICH Yorks.

Suite 3 une lusion-absorbtion part forme de sociétés civiles réalisant des l'Anna-Jacquin 97100 Boulogne CMA CONSEIL MANAGEMENT AUDITI opérations à finalité focative prévues à l'article Proposition du la CASTEL JACQUET ET ASSO-l' De ces italuts modifiés ou complètes it so, 37000 Nanteire en remissables aux sociétes immobilières men-de Monsieur ASCHENI tronnées su 2º du de l'article R 313-31 (demeurant 1º du code : e la construction qui ent pris la Bray (60850), urie l'usion-absorction par l'forme de sociétés divites réalisant des l'Suivant un

article F 313-17 en qualité de presider
De ces itatuts modifiés ou complètes il ministration. Monsieur sit extra:
TIER et en qualité de

porter, en qualité de le aux tomples titu-maST and YOUNG O D. le coule-and leuvieme arrondisse, commirce et gest la reclisation d'operations à finalité locative : revues au ill du l'et au il de l'article f 313-17 du code de la cons-truction et de l'habitation 368 315.

Cession des parts : Toute cession de arts doi être préalablement autorisée

depotee au ingistre ou commerce et

Pour extrait. La géranie, AIPAL LA HENIN. 115091 -

SOCIETE CIV LE

Société d au capita. 750

RCS Par

generale extraooctobre mit neut i Il a été décide

- De transfère 117-119, quai de \ arrondissement)

conséquence l'arti — De complèter tuta de la sociéte conformité avec le cables aux societ tionnées au 2º du du code de la cons forme de société l'article R. 313-17.

De ces statuts mi est extrait

Objet : L'objet e est la realisation d locative prevues a. l'article R 313-17 truction et de l'hab

Cession des par parts doit être pr par décision extrao-L'inscription

déposée au regi des sociétés de

115038 - Pet

MER.

au capital o Siège :

20, rue de 75020 A.C.S. Paris &

Suivant un procesmai 1994, L'assemblée gêne

décide - De transforme société anonyme à c sans creation d'un é

De mettre fin au de Monsieur Francoe - De nommer en

trateurs : Madame demeurant 19, rue R gy-en-Bray

Monsieur Alain rant 6 bis, cite Aubis arrondissement).

- Monsieur 19 rue f

Suivant un proces date. le conseil d'adm Monsieur Alain MONTI

> Mention sera tai commerce et des

ALLO TURF, société tal de 250 000 F, sir Joultrey, 75017 P/ 391 074 176 Pr avec A.A. en da pris acte de i Moneieur L'

PATENT

REEL: 8613 FRAME: 0149

RECORDED: 07/22/1997

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE MANY 1 8 1897 &

In repatent application of:

Befinart et al.

Patent No.: 5,270,317

Granted: December 14, 1993

Serial No. 08/794,497

Filing Date: November 20, 1991

For: N-Substituted Heterocyclic Derivatives, Their Preparation And The Pharmaceutical Compositions In Which They Are Present

Assistant Commissioner for Patents Box Patent Extension Washington, D.C. 20231

Dear Sir:

CERTIFICATE UNDER 37 C.F.R. 1.10(b)

Express Mail Label Number: <u>EM317281351US</u>

Date of Deposit: <u>(f No veuber 1997</u>

I hereby certify that this paper is being deposited with

I hereby certify that this paper is being deposited with the United Stated Postal Service "Express Mail Post Office to Addressee" Service on the indicated above and is addressed to: Asst. Commissioner for Patents Box Patent Extension, Washington, DC 20231

any & Lantip

Name

18 November 1997

Date

RECEIVED

DEC - 1 1997

PATENT EXTENSION A/C PATENTS

CERTIFICATION

Attached hereto is a duplicate of the application papers for extension of the term of United States Patent No. 5,270,317.

I hereby certify that the attached papers are true duplicate copies of the documents relating to our application for extension of the term of United States Patent No. 5,270,317.

Signed by me this 18^{11} day of November, 1997.

Respectfully submitted,

Michael D. Alexander Registration No. 36,080

Address: Sanofi Pharmaceuticlas, Inc. 9 Great Valley Parkway P.O. Box 3026 Malvern, PA 19355 Tele: (610) 889-8802

Facsimile: (610) 889-8799